CMMB Q4 2022 Earnings — Chemomab Therapeutics Ltd. Revenue & Financial Results | Market Cap Arena

CMMBChemomab Therapeutics Ltd.

$12M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$13,962

Operating Income

-$9M

Net Income

-$8M

EPS (Diluted)

$-2.84

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$43M

Total Liabilities

$7M

Stockholders' Equity

$36M

Cash & Equivalents

$14M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$13,962	-$11,050	-26.4%
Operating Income	-$9M	-$5M	-72.0%
Net Income	-$8M	-$5M	-64.3%